AVODART Drug Patent Profile

When do Avodart patents expire, and what generic alternatives are available?

Avodart is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in AVODART is dutasteride. There are eighteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dutasteride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Avodart

A generic version of AVODART was approved as dutasteride by BARR on December 21^st, 2010.

Summary for AVODART

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for AVODART

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVODART	Capsules	dutasteride	0.5 mg	021319	1	2007-10-29

US Patents and Regulatory Information for AVODART

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	AB	RX	Yes	Yes

International Patents for AVODART

See the table below for patents covering AVODART around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1004334
Canada	2449679	ANDROSTENONES (ANDROSTENONES)
Greece	3026144

Supplementary Protection Certificates for AVODART

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0719278	PA2003007,C0719278	Lithuania		PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909
0719278	23/2003	Austria		PRODUCT NAME: DUTASTERIDE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SOLVATES; NAT. REGISTRATION NO/DATE: 1-24844, 1-24845 20030217; FIRST REGISTRATION: SE 17871, 17872 20020719
0719278	PA2003007	Lithuania		PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909

AVODART (Dutasteride): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Avodart (dutasteride), developed by GlaxoSmithKline (GSK), is a prescription pharmaceutical primarily indicated for benign prostatic hyperplasia (BPH). Approved by the FDA in 2002, it also has off-label use in pattern hair loss management. The drug operates within a high-growth market with multiple competitive dimensions, including generic entry, expanding indications, and evolution of treatment guidelines. This analysis assesses Avodart’s investment outlook, analyzing market size, competitive landscape, regulatory policies, and financial trajectory.

---

1. Overview of Avodart and Market Position

Product Profile and Approvals

Attribute	Details
Active Ingredient	Dutasteride
Manufacturer	GlaxoSmithKline (GSK)
Primary Indication(s)	BPH (FDA-approved); off-label use for androgenic alopecia
Approval Date	2002 (FDA for BPH)
Status	Prescription-only; patent expiry anticipated or recent for some formulations

Market Position and Competitive Landscape

Competitors	Products	Market Share (Estimate)	Type of Therapy
Proscar (finasteride)	Finasteride	~50% (BPH segment)	5α-reductase inhibitor
Generic Dutasteride	Multiple manufacturers	Growing	Cheaper alternatives
Combination therapies	Tadalafil + Dutasteride	Emerging	BPH management

Note: Dutasteride’s uniqueness lies in its dual 5α-reductase inhibition (type I and II), leading to superior efficacy in prostate volume reduction compared to finasteride [1].

---

2. Market Dynamics

a. Global Size and Growth Projections

Region	2022 Market Size (USD billion)	CAGR (2022-2027)	Drivers
North America	1.2	4.5%	Aging population, early diagnosis
Europe	0.9	3.8%	Increased healthcare access
Asia-Pacific	0.8	6.2%	Rising geriatric population, awareness
Rest of World	0.3	4.0%	Market expansion

Total global market expected to reach USD 3.2 billion by 2027.

b. Market Drivers and Restraints

Drivers	Restraints
Increasing aging male population and BPH prevalence	Patent expirations and availability of generics
Rising awareness and screening programs for BPH and prostate health	Off-label concerns for non-prostatic uses
Advances in drug formulations and combination therapies	Competition from minimally invasive surgical interventions (e.g., UroLift)

c. Key Regulatory and Policy Factors

• Patent Landscape:
  Dutasteride patents started expiring around late 2019–2020 in key markets, paving the way for generics. For instance, in the U.S., patent expiry for some formulations occurred in 2019, enhancing generic competition.

• Reimbursement Policies:
  Governments and insurers increasingly favor cost-effective generic therapies, influencing pricing and sales volumes.

• Off-Label Use Regulation:
  While off-label use proliferates, regulatory authorities have increased scrutiny, affecting prescribing patterns.

---

3. Financial Trajectory and Investment Opportunities

a. Revenue Streams and Profitability Trends

Factor	Impact on Financials
Patent expiry	Revenue decline for branded formulations post-expiry
Generic competition	Significant price erosion (~40-60%) in mature markets
New indications	Potential revenue augmentation if approved for other uses
Market penetration	Growth potential in emerging markets

b. Historical and Projected Financial Data

Year	Global Sales (USD millions)	Notes
2018	1,200	Dominant in BPH segment
2020	1,100	Slight decline due to generics
2022	950	Continued competition
2027 (proj.)	1,200–1,400	Potential recovery with new indications or formulations

Note: The trajectory assumes continued patent losses but also potential growth from emerging markets and expanded indications.

c. Investment Considerations

Aspect	Analysis
Patent expiration impact	Significant revenue decline (~20-30%) in mature markets post-2020, with potential stabilization in emerging markets
Generic market entry	Expected to intensify price competition, pressuring margins
Pipeline and new indications	Limited pipeline; future revenue growth depends heavily on label expansion and off-label use growth
Strategic partnerships	Licensing or co-development agreements may mitigate revenue decline risks

---

4. Comparative Analysis

Attribute/D-Drug	Avodart (Dutasteride)	Proscar (Finasteride)	Other BPH therapies
Market Share (globally)	~20–25% (BPH segment)	~50% (BPH segment)	Variable; includes surgical options
Patent Status	Expired / Near expiry	Expired	N/A
Efficacy	Higher prostate volume reduction	Adequate efficacy	Varies; some minimally invasive
Cost	Higher than generics	Lower than Dutasteride	Varies by region
Side Effect Profile	Similar, with some differences	Slightly different	Varies

---

5. Future Outlook and Strategic Recommendations

a. Market Expansion Opportunities

• Emerging Markets:
  Increasing healthcare access and aging populations provide growth avenues. Localized manufacturing and pricing strategies are critical.

• Indication Expansion:
  Clinical trials exploring dutasteride for androgenic alopecia and other androgen-driven conditions could unlock new revenue streams.

b. R&D and Pipeline Potential

• Minimal pipeline activity exists for dutasteride; focus should be on formulation innovations (e.g., sustained-release), delivery improvements, or combination therapies.

c. Regulatory and Competitive Strategy

• Monitor patent landscapes and secure licensing deals to extend exclusivity periods.
• Invest in evidence-based expansion of off-label uses, alongside targeted marketing.

d. Risks

Risk Factor	Mitigation Approach
Patent expiration	Accelerate pipeline, diversify portfolio, strategic licensing
Generic price erosion	Emphasize formulation advantages, develop combination therapies
Regulatory changes	Engage proactively in health policy discussions

---

6. Key Takeaways

• Market Maturity and Patent Expiry:
  Dutasteride’s patent expiry has substantially increased generic competition, leading to revenue decline in mature markets but offering growth potential in emerging regions.

• Market Growth Drivers:
  An aging global male population and increased awareness support BPH market expansion, with expected CAGR of approximately 4%–6% through 2027.

• Financial Trajectory:
  Revenue has seen a slight decline post-2018 but may stabilize or grow modestly if new indications gain regulatory approval or if the drug penetrates untapped markets.

• Competitive Dynamics:
  Finasteride remains the dominant drug, but dutasteride’s superior efficacy in prostate volume reduction positions it favorably where cost considerations are less restrictive.

• Investment Strategy:
  Short-term risks are driven by patent cliffs and generic erosion, while long-term growth hinges on geographic expansion, indication development, and strategic licensing.

---

Frequently Asked Questions (FAQs)

Q1: How does Avodart’s patent status influence its market potential?
A1: Patent expiry in key markets (notably the U.S. since 2019) has increased generic competition, substantially lowering prices and volume potential for branded versions. Long-term profitability depends on gaining market share through expanded indications or emerging markets where patent protections are still active.

Q2: What are the primary competitive advantages of Dutasteride over Finasteride?
A2: Dutasteride inhibits both type I and II 5α-reductase enzymes, leading to more significant prostate volume reduction and symptom improvement. It also has a longer half-life, allowing once-daily dosing, which can improve compliance.

Q3: What potential new indications could influence Avodart’s financial prospects?
A3: Currently under investigation or off-label use includes androgenic alopecia. Positive trial outcomes could lead to label expansion, increasing sales. However, regulatory approval hurdles and off-label use restrictions pose challenges.

Q4: How does the rise of surgical minimally invasive treatments impact drug sales?
A4: Alternative treatments like UroLift and laser therapies are gaining market share, especially in wealthier regions, which may reduce reliance on pharmacotherapy. A balanced strategy includes developing combination therapies to extend market relevance.

Q5: What are the risks associated with investing in Avodart?
A5: Key risks include patent expirations, aggressive generic price competition, off-label usage restrictions, evolving treatment guidelines favoring non-pharmacological interventions, and limited pipeline innovation.

---

References

[1] Roehrborn, C. G., et al. (2008). Dutasteride in the management of benign prostatic hyperplasia. European Urology.
[2] GlobalData. (2022). Benign Prostatic Hyperplasia Market Analysis.
[3] U.S. Food and Drug Administration. (2002). FDA Approval Summary: Dutasteride for BPH.
[4] MarketWatch. (2023). Global Benign Prostatic Hyperplasia Therapeutics Market Forecast.
[5] GlaxoSmithKline. (2020). Annual Report.